Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R, Jager Vd, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE; PanACEA consortium. Stemkens R, et al. Among authors: boeree mj. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0068323. doi: 10.1128/aac.00683-23. Epub 2023 Sep 28. Antimicrob Agents Chemother. 2023. PMID: 37768317 Free PMC article.
Recent advances in the treatment of tuberculosis.
Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR Jr, Kherabi Y, Lange C, Lienhardt C, McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L; Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Motta I, et al. Among authors: boeree m. Clin Microbiol Infect. 2023 Jul 22:S1198-743X(23)00339-7. doi: 10.1016/j.cmi.2023.07.013. Online ahead of print. Clin Microbiol Infect. 2023. PMID: 37482332 Review.
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement.
Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, Dheda K, Dudnyk A, Farhat MR, Gagneux S, Grobusch MP, Gröschel MI, Guglielmetti L, Kontsevaya I, Lange B, van Leth F, Lienhardt C, Mandalakas AM, Maurer FP, Merker M, Miotto P, Molina-Moya B, Morel F, Niemann S, Veziris N, Whitelaw A, Horsburgh CR Jr, Lange C; TBnet and RESIST-TB networks. Domínguez J, et al. Among authors: boeree mj. Lancet Infect Dis. 2023 Apr;23(4):e122-e137. doi: 10.1016/S1473-3099(22)00875-1. Epub 2023 Feb 28. Lancet Infect Dis. 2023. PMID: 36868253 Review.
Protocol for a feasibility randomized controlled trial to evaluate the efficacy, safety and tolerability of N-acetylcysteine in reducing adverse drug reactions among adults treated for multidrug-resistant tuberculosis in Tanzania.
Mpagama SG, Mvungi HC, Mbelele PM, Semvua HH, Liyoyo AA, de Guex KP, Sloan D, Kibiki GS, Boeree M, Phillips PPJ, Heysell SK. Mpagama SG, et al. Among authors: boeree m. Pilot Feasibility Stud. 2023 Apr 1;9(1):55. doi: 10.1186/s40814-023-01281-7. Pilot Feasibility Stud. 2023. PMID: 37005695 Free PMC article.
Building sustainable clinical trial sites in Sub-Saharan Africa through networking, infrastructure improvement, training and conducting clinical studies: The PanACEA approach.
Mekota AM, Gillespie SH, Hoelscher M, Diacon AH, Dawson R, Churchyard G, Sanne I, Minja L, Kibiki G, Maboko L, Lakhi S, Joloba M, Alabi A, Kirenga B, McHugh TD, Grobusch MP, Boeree MJ; PanACEA consortium. Mekota AM, et al. Among authors: boeree mj. Acta Trop. 2023 Feb;238:106776. doi: 10.1016/j.actatropica.2022.106776. Epub 2022 Dec 8. Acta Trop. 2023. PMID: 36502888
204 results